Contributions
Abstract: P936
Type: Poster Sessions
Abstract Category: Therapy - Risk management for disease modifying treatments
Background: Females diagnosed with relapsing remitting multiple sclerosis (RRMS) are usually in the child bearing age. It is unclear whether the decision regarding immunomodulatory treatment should be influenced by pregnancy in the near future.
Objective: To evaluate the effect of disease modified therapies (DMTs) for multiple sclerosis (MS) on fertility, pregnancy outcomes and disease progression.
Methods: Retrospective data, obtained from RRMS patients that gave birth between 2002-2017, was analyzed. Patients were divided into three groups according to the use of DMTs: (1) patients that were not treated in the 3 months prior to pregnancy (2) patients that were treated in the 3 months prior to pregnancy (3) patients that were treated during pregnancy. A multivariate analysis adjusted to age, disease severity, known fertility problems and previous pregnancies was performed. Outcomes in the study included: delivery week, birth weight, child percentile, birth type, pregnancy complications, need for fertility treatment, time to pregnancy, attacks during pregnancy and one year postpartum and change in the EDSS score one year postpartum.
Results: One hundred and twenty five RRMS patients with total of 219 live births were evaluated; mean±SD age at birth 31.8±4.6yr, range 20-45yr, median (IQR) disease duration 7.6 (4.3-11.7)yr, use of DMTs varied from 0-5yr; 13 patients were treated with DMTs during pregnancy. Total of 12 patients (divided equally between the groups) needed fertility treatment in order to conceive. No significant differences were found between groups regarding: (1) the need for fertility treatment and time to pregnancy (2) pregnancy outcomes and pregnancy complications (3) attacks during and after pregnancy and changes in EDSS score.
Conclusion: Use of DMTs for MS did not affect the fertility and pregnancy outcomes. The decision regarding DMTs treatment in RRMS patients during child bearing years should not be influenced by the question of pregnancy in the near future.
Disclosure: Pardo Keshet: nothing to disclose. Katorza Eldad: nothing to disclose. Yael Stern: nothing to disclose. Maria Bovim-Rabay: nothing to disclose. Gili Givaty: nothing to disclose. Tomer Ziv-Baran: nothing to disclose. Menascu Shay: Consulting fees: (Genzyme); contracted research (Bayer, Biogen Idec, EMD Serono, Genzyme, Roche). Dolev Mark: Consulting fees: (Genzyme); contracted research (Bayer, Biogen Idec, EMD Serono, Genzyme, Roche). Magalashvili David: Consulting fees: (Genzyme); contracted research (Bayer, Biogen Idec, EMD Serono, Genzyme, Roche). Achiron Anat: Consulting fees: (EMD Serono, Genzyme, Roche); contracted research (Bayer, Biogen Idec, EMD Serono, Genzyme, Roche).
Abstract: P936
Type: Poster Sessions
Abstract Category: Therapy - Risk management for disease modifying treatments
Background: Females diagnosed with relapsing remitting multiple sclerosis (RRMS) are usually in the child bearing age. It is unclear whether the decision regarding immunomodulatory treatment should be influenced by pregnancy in the near future.
Objective: To evaluate the effect of disease modified therapies (DMTs) for multiple sclerosis (MS) on fertility, pregnancy outcomes and disease progression.
Methods: Retrospective data, obtained from RRMS patients that gave birth between 2002-2017, was analyzed. Patients were divided into three groups according to the use of DMTs: (1) patients that were not treated in the 3 months prior to pregnancy (2) patients that were treated in the 3 months prior to pregnancy (3) patients that were treated during pregnancy. A multivariate analysis adjusted to age, disease severity, known fertility problems and previous pregnancies was performed. Outcomes in the study included: delivery week, birth weight, child percentile, birth type, pregnancy complications, need for fertility treatment, time to pregnancy, attacks during pregnancy and one year postpartum and change in the EDSS score one year postpartum.
Results: One hundred and twenty five RRMS patients with total of 219 live births were evaluated; mean±SD age at birth 31.8±4.6yr, range 20-45yr, median (IQR) disease duration 7.6 (4.3-11.7)yr, use of DMTs varied from 0-5yr; 13 patients were treated with DMTs during pregnancy. Total of 12 patients (divided equally between the groups) needed fertility treatment in order to conceive. No significant differences were found between groups regarding: (1) the need for fertility treatment and time to pregnancy (2) pregnancy outcomes and pregnancy complications (3) attacks during and after pregnancy and changes in EDSS score.
Conclusion: Use of DMTs for MS did not affect the fertility and pregnancy outcomes. The decision regarding DMTs treatment in RRMS patients during child bearing years should not be influenced by the question of pregnancy in the near future.
Disclosure: Pardo Keshet: nothing to disclose. Katorza Eldad: nothing to disclose. Yael Stern: nothing to disclose. Maria Bovim-Rabay: nothing to disclose. Gili Givaty: nothing to disclose. Tomer Ziv-Baran: nothing to disclose. Menascu Shay: Consulting fees: (Genzyme); contracted research (Bayer, Biogen Idec, EMD Serono, Genzyme, Roche). Dolev Mark: Consulting fees: (Genzyme); contracted research (Bayer, Biogen Idec, EMD Serono, Genzyme, Roche). Magalashvili David: Consulting fees: (Genzyme); contracted research (Bayer, Biogen Idec, EMD Serono, Genzyme, Roche). Achiron Anat: Consulting fees: (EMD Serono, Genzyme, Roche); contracted research (Bayer, Biogen Idec, EMD Serono, Genzyme, Roche).